MeSH D002277 - carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009375:Glandular and epithelial neoplasms
0 Companies
0 Drugs
Success rate
D002277:
Carcinoma
D000069295:Mammary analogue secretory carcinoma
0 Companies
0 Drugs
Success rate
D000077216:Ovarian epithelial carcinoma
D000077274:Nasopharyngeal carcinoma
D000230:Adenocarcinoma
D002278:Carcinoma in situ
0 Companies
0 Drugs
Success rate
D002280:Basal cell carcinoma
D002281:Basosquamous carcinoma
0 Companies
0 Drugs
Success rate
D002286:Ehrlich tumor carcinoma
0 Companies
0 Drugs
Success rate
D002287:Krebs 2 carcinoma
0 Companies
0 Drugs
Success rate
D002291:Papillary carcinoma
0 Companies
0 Drugs
Success rate
D002294:Squamous cell carcinoma
D002295:Transitional cell carcinoma
D018196:Adenosquamous carcinoma
0 Companies
0 Drugs
Success rate
D018286:Giant cell carcinoma
0 Companies
0 Drugs
Success rate
D018287:Large cell carcinoma
0 Companies
0 Drugs
Success rate
D018288:Small cell carcinoma
D018289:Verrucous carcinoma
0 Companies
0 Drugs
Success rate
D018827:Lewis lung carcinoma
0 Companies
0 Drugs
Success rate
D065646:Anaplastic thyroid carcinoma
0 Companies
0 Drugs
Success rate
D000093284:Non-muscle invasive bladder neoplasms
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
63%15/24
Phase 2
22%8/37
Phase 3
21%3/14
Approved: 3Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use